4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.

Objective: To compare the efficacy and toxicity of 4-aminopyridine and 3,4-diaminopyridine in patients with multiple sclerosis.

Design: Intervention study with a before-after design and a randomized, double-blind, crossover design.

Setting: University referral center.

Occlusion of the retinal vasculature after trabeculectomy with mitomycin C.

A 45-year-old male underwent a trabeculectomy with mitomycin C for a secondary glaucoma after complicated cataract surgery. Because of early bleb failure a needling procedure with subconjunctival injection of mitomycin C was performed. Five days postoperatively the patient developed an occlusion of both the arterial and venous retinal vasculature.

4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.

In a recent randomized, double-blind, placebo-controlled crossover trial, we demonstrated efficacy of 4-aminopyridine (4-AP) in improving disability of patients with multiple sclerosis (MS). Here we describe the relationship between dosage, serum level, efficacy, and safety of intravenously and orally administered 4-AP in the same group of 70 MS patients. After both intravenous and oral administration there was a significant relationship between serum levels and 4-AP doses used (p < 0.

4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.

This study reports on the neurophysiological measurements that were performed in the context of a randomized, double-blind, placebo-controlled, cross-over study with intravenously administered 4-aminopyridine (4-AP) in 70 patients with definite multiple sclerosis (MS). A beneficial effect of 4-AP was found for both visual evoked response and eye movement registration parameters. This study extends the experimental data obtained on animal nerve fibers, showing that 4-AP can improve impulse conduction in demyelinated nerve, to clinical data which indicate that 4-AP induces an objective improvement in the central nervous system function in MS-patients.

A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.

In a randomized, double-blind, placebo-controlled pilot study, we examined the effect of Org 2766--a corticotropin (4-9) analogue--on neurotoxicity in 28 patients with lymphoma who were treated with combination chemotherapy containing Vinca alkaloids (vincristine and vinblastine). The patients received a total dose of 12 mg of vincristine in the case of non-Hodgkin's lymphoma and a total dose of 16 mg of vincristine in the case of Hodgkin's disease. Moreover, the patients with Hodgkin's disease received a mean total dose of 84 mg of vinblastine.